Ligand Pharmaceuticals, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, announced the expansion of Icagen’s license agreement with Roche and initiation of a new program focused on a novel ion channel target relevant to neurodegenerative disease.
This new program is an addition to Icagen’s initial neurology program with Roche on another novel CNS target.
Read more about Ligand Pharmaceuticals here.
Image by aymane jdidi from Pixabay
